

AMENDMENTS**In the claims**

Please amend the claims as follows, without prejudice or disclaimer:

Cancel claims 1-4, 10, 11, 14, 15, and 17-22.

Amend claim 5.

1. (Canceled) A prostate specific antigen (PSA) derived peptide that is capable of eliciting an immune response comprising a sequence of the Formula 1:



wherein $n = 0$ or 1 ;

each X_1 is independently selected from leucine or methionine;

each X_2 is independently selected from valine or leucine; and

each X is independently selected from any amino acid,


and fragments, elongations, analogs or derivatives of the PSA derived peptide.

2. (Canceled) A PSA derived peptide according to claim 1 selected from the group consisting of MWVPVVFL (SEQ ID NO: 1), VLVHPQVWL (SEQ ID NO: 2), and KLQCVDLHV (SEQ ID NO: 3), or a fragment, analog, derivative or elongation of the PSA derived peptide.

3. (Canceled) A PSA derived peptide according to claim 1 selected from the group consisting of MWVPVVFL (SEQ ID NO: 1), VLVHPQVVL (SEQ ID NO: 2), and KLQCVDLHV (SEQ ID NO: 3).

4. (Canceled) A fusion protein comprising the PSA peptide as described in any one of claims 1 to 3.

5. (Presently amended) An isolated nucleic acid molecule encoding an immunogenic peptide derived from prostate-specific antigen, the peptide being capable of eliciting an immune response for treating prostate cancer and consisting of an amino acid sequence as defined by Formula 1:



wherein

$n = 0$ or 1 ;

each X_1 is independently selected from leucine or methionine;

each X_2 is independently selected from valine or leucine; and

- each X is independently selected from any amino acid,
and ~~fragments, elongations,~~ analogs or derivatives of the PSA derived peptides.
6. (Previously amended) An isolated nucleic acid encoding a PSA derived peptide according to claim 5 comprising:
 - a) the nucleic acid sequence as shown in any one of SEQ ID NOS.:7-9 wherein T may also be U;
 - b) a nucleic acid sequence that is complementary to a nucleic acid sequence of (a);
 - c) a nucleic acid sequence that has at least 90% homology to a nucleic acid sequence of (a) or (b);
 - d) a nucleic acid sequence that is an analog of a nucleic acid sequence of (a), (b), or (c); or
 - e) a nucleic acid sequence that hybridizes to a nucleic acid sequence of (a), (b), (c), or (d) under stringent hybridization conditions.
 7. (Originally filed) A nucleic acid molecule encoding a PSA derived peptide according to claim 5 having a sequence selected from the group consisting of: SEQ ID NO. 7, SEQ ID NO. 8, and, SEQ ID NO. 9.
 8. (Originally filed) An expression vector comprising a nucleic acid molecule of claim 5 and regulatory sequences suitable for expression of the nucleic acid molecule.
 9. (Previously amended) An isolated host cell transformed with an expression vector of claim 8.
 10. (Canceled) A composition for eliciting an immune response in an animal comprising (a) an effective amount of a peptide according to any one of claims 1, 2 or 3; or (b) an effective amount of a fusion protein according to claim 4, in admixture with a suitable diluent or carrier.
 11. (Canceled) The composition of claim 10 further comprising an adjuvant.
 12. (Originally filed) A composition for eliciting an immune response in an animal comprising an effective amount of a nucleic acid molecule of claim 5 in admixture with a suitable diluent or carrier.
 13. (Originally filed) The composition of claim 12 further comprising an adjuvant.

14. (Canceled) A use of an effective amount of a peptide according to any one of claims 1 to 3 to prepare a medicament to elicit an immune response in an animal.
15. (Canceled) A use of an effective amount of a fusion protein according to claim 4 to elicit an immune response in an animal.
16. (Originally filed) A method of eliciting an immune response in an animal comprising administering an effective amount of a nucleic acid molecule of claim 5 to the animal.
17. (Canceled) A use of an effective amount of a composition according to any one of claims 10 to 13 to prepare a medicament to elicit an immune response in an animal.
18. (Canceled) A use of an effective amount of a peptide according to any one of claims 1 to 3 to prepare a medicament to treat cancer.
19. (Canceled) A use of an effective amount of a fusion protein according to claim 4 to prepare a medicament to treat cancer.
20. (Withdrawn) A use of an effective amount of a nucleic acid molecule according to any one of claims 5 to 7 to prepare a medicament to treat cancer.
21. (Canceled) A use of an effective amount of a composition according to any one of claims 10 to 13 to prepare a medicament to treat cancer.
22. (Canceled) A use according to any one of claims 18 to 21 wherein the cancer is prostate cancer.